Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-474-9 | CAS number: 107-22-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- (1999)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- (1998)
- Qualifier:
- according to guideline
- Guideline:
- other: EC Commission Directive 87/302/EEC of Nov 18, 1987, Part B: Methods for the determination of toxicity: Teratogenicity study (rodent and non-rodent), Official Journal of the European Communities; No L 133, pp. 24-26 (1988)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Glyoxal
- EC Number:
- 203-474-9
- EC Name:
- Glyoxal
- Cas Number:
- 107-22-2
- Molecular formula:
- C2H2O2
- IUPAC Name:
- oxalaldehyde
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: B 61
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Stability under test conditions: Proven by reanalysis after the in life phase of the study
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Boehringer Ingelheim Pharma KG, Biberach an der Riss, Germany
- Age at study initiation: 9 to 11 weeks old
- Weight at study initiation: 228.9 – 233.4 g
- Housing: The rats were housed singly from day 0- 20 p.c. in type DK 111 stainless steel wire mesh cages supplied by BECKER & CO ., Castrop-Rauxel, FRG
- Diet (e.g. ad libitum): ground Kliba maintenance diet rat/mouse/hamster meal, ad libitum
- Water (e.g. ad libitum): drinking water of tap water quality, ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24°C
- Humidity (%): 30 - 70%
- Air changes (per hr): fully air-conditioned rooms
- Photoperiod (hrs dark / hrs light): 12 h /12 h
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The test substance solutions were analyzed by HPLC
- Details on mating procedure:
- Two to three untreated females were mated with one untreated fertile male rat of the same breed. Mating took place from ca. 16.00 hours to ca. 7.30 hours on the following day; the mating period was therefore about 15 to 16 hours.
When sperm was detected in the vaginal smear, the females were considered as fertilized and the day was designated as day 0 of gestation. - Duration of treatment / exposure:
- d 6-19 post coitum
- Frequency of treatment:
- 7 d/wk
- Duration of test:
- d 6-20 post coitum
Doses / concentrationsopen allclose all
- Dose / conc.:
- 5 mg/kg bw/day
- Remarks:
- actual ingested (active ingredient)
- Dose / conc.:
- 25 mg/kg bw/day
- Remarks:
- actual ingested (active ingredient)
- Dose / conc.:
- 125 mg/kg bw/day
- Remarks:
- actual ingested (active ingredient)
- No. of animals per sex per dose:
- 25 animals /group were used
- Control animals:
- yes, concurrent no treatment
Examinations
- Maternal examinations:
- - The animals were checked daily, at least once for clinical symptoms and twice for mortality on working days. On Saturdays, Sundays or public holidays, the animals were only checked once a day;
- Body weight changes and food consumption were recorded; - Ovaries and uterine content:
- Following parameters were examined:
Gravid uterine weight, number of corpora lutea, number and distribution of implantations sites classified as live foetuses and dead implantations. Dead implantations comprised early resorptions, late resorptions and dead foetuses. - Fetal examinations:
- The foetuses were dissected from the uterus, sexed weighed and further investigated for any external, soft tissue and/or skeletal findings.
- Statistics:
- - Pairwise comparison of each dose group with the control group using FISHER´s EXACT test (one-sided) for the hypothesis of equal proportions (for parameters female mortality, females pregnant at terminal sacrifice, number of litters with fetal findings)
- Pairwise comparison of each dose group usingWILCOXON test (one-sided) for the hypothesis of equal medians (for parameters of proportions of fetuses with malformations, variations and/or unclassified observations in each litter)
- Simultaneous comparison of all dose groups with the control group using the DUNNETT-test (two-sided) for the hypothesis of equal means (for all other parameters examined and not mentioned above) - Indices:
- The conception rate (CR) as well as the pre- and post- implantation losses (Pre-I¸Post-I) were calculated.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Signs of toxicity only were seen in the high dose group treated with 125 mg/kg bw/day of Glyoxal; no such signs could be evidenced in the low and mid dose groups. In fact, in the high dose group, sporadically occurring, transient salivation was observed.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- In the high dose group, statistically significantly lowered corrected body weight gain (about 29% below control) and reduced mean carcass weight was reported.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significantly reduced food consumption (ca. 7% below control for the period from day 6 to day 19 p.c.) were reported.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Mean gravid uterus weight was inconspicuous.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
Maternal developmental toxicity
- Number of abortions:
- not specified
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not specified
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not specified - Changes in number of pregnant:
- not specified
- Details on maternal toxic effects:
- No treatment-related and/or biologically relevant differences between the test groups (treated and control) in conception rate, mean number of corpora lutea, implantation sites, pre- and post-implantation losses, number of resorptions, and in viable foetuses could be evidenced. Differences, when they occurred, were within the normal range of deviations for animals of the strain and age used.
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 25 mg/kg bw/day
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed - Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- The sex distribution of the fetuses in test groups 25 and 125 mg/kg body weight/day was comparable with that of the control fetuses . The differences observed in comparison to the control were without any biological relevance .
- Changes in litter size and weights:
- not specified
- Changes in postnatal survival:
- not specified
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Anophthalmia of left eye was recorded for one male control fetus. Another eye malformation occurred in one low dose female fetus in the form of microphthalmia . Moreover, another female fetus of this dose group had multiple external (and some corresponding skeletal) malformations
substantiated by cleft palate, gastroschisis, brachydactyly and micromelia of the right forelimb and a mairotated right hindlimb . Finally, one female of high dose dam had a short snout and a cleft palate ; these findings are correlated to different skull malformations of the same fetus. - Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Malpositioned and bipartite sternebra (with unchanged cartilage) occurred in one control, one mid dose and one high
dose fetus each. Cleft sternum (with split cartilage) was observed for 2 male fetuses (control and low dose). Absent lumbar vertebra was recorded for one male control fetus and one high dose female fetus; the latter fetus had also a deformed ischium and severely ma!formed skull bones, which are in-line with the external malformations (i .e.short snout, cleft palate) observed in this fetus. Finally, one female fetus of low dose showed various skeletal malformations with
or without involvement of the cartilaginous structures (affecting sternebrae, ribs, different sections of the vertebral column, skull, metacarpal and metatarsal bones) in addition to multiple external malformations (e .g . cleft palate, gastroschisis, brachydacty!y and microme!ia). - Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In the control group one female fetus showed a situs inversus, while in one male fetus of control rat an bilateral enlargement of the ventricular
chambers occurred. The same heart malformation was also observed for one mid dose female fetus. Soft tissue variations were detected in each group including the control.
Effect levels (fetuses)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 125 mg/kg bw/day
- Basis for effect level:
- other: teratogenicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 125 mg/kg bw/day
- Basis for effect level:
- other: fetotoxicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
